Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Colorectal Neoplasms 16Uterine Cervical Neoplasms 5Rectal Neoplasms 5Pancreatic Neoplasms 5Colonic Neoplasms 4Stomach Neoplasms 3Neoplasm Metastasis 3Prostatic Neoplasms 2Neoplasms 2Hemangiosarcoma 2Diabetes Mellitus, Insulin-Dependent, 12 2Carcinoma, Non-Small-Cell Lung 2Urinary Bladder Neoplasms 1Squamous Cell Carcinoma of Head and Neck 1Sarcoma 1Resectable MMR-deficient Solid Tumors 1Refractory Metastatic Microsatellite Stable Colorectal Cancer (MSS-CRC) 1Parkinson Disease 4, Autosomal Dominant Lewy Body 1Pancreatic Cancer Metastatic 1Ovarian Neoplasms 1Oropharyngeal Neoplasms 1Microsatellite Stable Rectal Carcinoma 1Melanoma 1Lymphoma 1Gliosarcoma 1Glioma 1Glioblastoma 1Fibrolamellar hepatocellular carcinoma 1Esophageal Neoplasms 1Endometrial Neoplasms 1

Interventions

Gemcitabine 157Cisplatin 116pembrolizumab 80Nivolumab 42Carboplatin 42Paclitaxel 41Mitomycin 41Cystectomy 40Docetaxel 38atezolizumab 33Magnetic Resonance Spectroscopy 31durvalumab 30Radiotherapy 29BCG Vaccine 26avelumab 24Specimen Handling 24Doxorubicin 23enfortumab vedotin 22Fluorouracil 20Cystoscopy 20Methotrexate 17Vinblastine 16Standard of Care 15Filgrastim 14Transurethral Resection of Bladder 13Sunitinib 13Ipilimumab 13vinflunine 125-aminolevulinic acid hexyl ester 12tremelimumab 11

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Urinary Bladder Neoplasms × balstilimab × Clear all
NCT04430036 2024-04-04

AGEN1884 Plus AGEN2034 Combined With Cisplatin-Gemcitabine for Muscle-Invasive Bladder Cancer

The University of Texas Health Science Center at San Antonio

Phase 2 Terminated
4 enrolled 9 charts
Genitourinary

Urinary Bladder Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡